User:Y-S.Ko/Wikipedia course/Pharmacology/A-J
From Wikipedia, the free encyclopedia
| Magnesium (increases motility) | |
|---|---|
| Aluminium (decreases motility) | |
| Calcium | |
| Sodium | |
| Combinations and complexes of aluminium, calcium and magnesium | |
| H2 antagonists ("-tidine") | |
|---|---|
| Prostaglandins (E)/ analogues ("-prost-") | |
| Proton-pump inhibitors ("-prazole") | |
| Potassium-competitive acid blockers ("-prazan") | |
| Others | |
| Combinations | |
| |
Drugs for functional gastrointestinal disorders (A03) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drugs for functional bowel disorders |
| ||||||||||||
| Belladonna and derivatives (antimuscarinics) |
| ||||||||||||
| Propulsives | |||||||||||||
| Stool softeners | |
|---|---|
| Stimulant laxatives | |
| Bulk-forming laxatives | |
| Lubricant laxatives | |
| Osmotic laxatives | |
| Enemas | |
| Opioid antagonists | |
| Others | |
| Rehydration | |
|---|---|
| Intestinal anti-infectives | |
| Intestinal adsorbents |
|
| Antipropulsives (opioids) |
|
| Intestinal anti-inflammatory agents |
|
| Antidiarrheal micro-organisms | |
| Other antidiarrheals | |
| |
| |||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
| Fat soluble |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Water soluble |
| ||||||||
| Combinations | |||||||||
| |||||||||
| Major |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trace |
| ||||||||||||
| Ultratrace |
| ||||||||||||
| |||||||||||||
| Androgens (incl. AASTooltip anabolic–androgenic steroid) |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiandrogens |
| ||||||||||||
| |||||||||||||
| Amino acids and derivatives | |
|---|---|
| Enzymes |
|
| Other | |
| Antiplatelet drugs |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anticoagulants |
| ||||||||||||||
| Thrombolytic drugs/ fibrinolytics | |||||||||||||||
| Non-medicinal | |||||||||||||||
| |||||||||||||||
| Antihemorrhagics (coagulation) |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antifibrinolytics | |||||||||||
| Erythropoietins | |
|---|---|
| Iron supplements | |
| Vitamin B12 and folic acid supplements | |
| HIF prolyl-hydroxylase inhibitors | |
| Other | |
Blood substitutes and perfusion solutions (B05) | |
|---|---|
| Blood and related products (B05A) | |
| Intravenous solutions (B05B) | |
| Irrigating solutions (B05C) | |
| Others (B05D, B05X) |
|
Other hematological agents (B06) | |
|---|---|
| Enzymes (B06AA) | |
| Drugs used in hereditary angioedema (B06AC) | |
| Others | |
| Bufadienolides |
| ||||||
|---|---|---|---|---|---|---|---|
| Cardenolides |
| ||||||
| |||||||
| Channel blockers |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receptor agonists and antagonists |
| ||||||||||||
| Ion transporters |
| ||||||||||||
| |||||||||||||
Cardiac stimulants excluding cardiac glycosides (C01C) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenergic and dopaminergic agents |
| ||||||||||||||
| Phosphodiesterase inhibitors (PDE3I) | |||||||||||||||
| Other cardiac stimulants | |||||||||||||||
| |||||||||||||||
| Nitrovasodilators | |
|---|---|
| Quinolone vasodilators | |
| Others | |
| |
| Sympatholytics (antagonize α-adrenergic vasoconstriction) |
| ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other antagonists |
| ||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| Nitrovasodilator (arterioles and venules) | |
|---|---|
| Hydrazinophthalazines (arterioles) | |
| Potassium channel openers (arterioles) | |
| Calcium channel blockers (arterioles) |
|
| |
| Sulfonamides (and etacrynic acid) |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Potassium-sparing (at CD) |
| ||||||||
| Osmotic diuretics (PT, DL) | |||||||||
| Vasopressin receptor inhibitors (DCT and CD) | |||||||||
| Other | |||||||||
| Combination products | |||||||||
| |||||||||
| Phenylethanolamine derivatives | |
|---|---|
| Alpha blockers |
|
| Niacin and derivatives | |
| Purine derivatives | |
| Ergot alkaloids | |
| Other peripheral vasodilators | |
| Antihemorrhoidals for topical use |
| ||||||
|---|---|---|---|---|---|---|---|
| Antivaricose therapy |
| ||||||
| Capillary stabilising agents |
| ||||||
| β, non-selective | |
|---|---|
| β1-selective | |
| β2-selective | |
| α1- + β-selective | |
| |
| Calcium |
| ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Potassium |
| ||||||||||||||||||||||||
| Sodium |
| ||||||||||||||||||||||||
| Chloride |
| ||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||
| ACE inhibitors ("-pril") |
|
|---|---|
| AIIRAs ("-sartan") | |
| Renin inhibitors ("-kiren") | |
| Dual ACE/NEP inhibitors | |
| Neprilysin inhibitors | |
| |
| GI tract |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liver |
| ||||||||||||
| Blood vessels |
| ||||||||||||
| Combinations | |||||||||||||
| Other | |||||||||||||
| |||||||||||||
Emollients and protectives (D02) | |
|---|---|
| Emollients and protectives | |
| Protectives against UV-radiation | |
| Cicatrizants | |
|---|---|
| Proteolytic enzymes | |
| Antihistamines for topical use | |
|---|---|
| Anesthetics for topical use | |
| Others |
|
| Topical |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Systemic |
| ||||||||
| |||||||||
| Antibiotics |
| ||||||
|---|---|---|---|---|---|---|---|
| Chemotherapeutics |
| ||||||
| Glucocorticoids |
| ||||
|---|---|---|---|---|---|
| Antiglucocorticoids |
| ||||
| Synthesis modifiers | |||||
| |||||
| Acridine derivatives | |
|---|---|
| Biguanides and amidines | |
| Phenol and derivatives | |
| Nitrofuran derivatives | |
| Iodine products | |
| Quinoline derivatives | |
| Quaternary ammonium compounds | |
| Mercurial products | |
| Silver compounds | |
| Alcohols | |
| Other | |
| |
| Ointment dressings with anti-infectives | |
|---|---|
| Other | |
| Antibacterial | |
|---|---|
| Keratolytic | |
| Anti-inflammatory | |
| Antibiotics | |
| Hormonal | |
| Retinoids | |
| Other | |
| Combinations | |
| |
Other dermatological preparations (D11) | |
|---|---|
| Anti-seborrheics | |
| Skin lightening | |
| Skin darkening | |
| Anti-inflammatories | |
| Alopecia treatments | |
| Hair growth inhibitors | |
| Others |
|
| Antibiotics | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Arsenic compounds | |||||||||
| Quinoline derivatives | |||||||||
| Organic acids | |||||||||
| Sulfonamides | |||||||||
| Antifungals |
| ||||||||
| Other | |||||||||
| Cervical ripening |
| ||||
|---|---|---|---|---|---|
| Contraction induction | |||||
| |||||
Birth control methods | |||||||
|---|---|---|---|---|---|---|---|
| Related topics | |||||||
| Long-acting reversible contraception (LARC) | |||||||
| Sterilization |
| ||||||
| Hormonal contraception |
| ||||||
| Barrier Methods | |||||||
| Emergency Contraception (Post-intercourse) | |||||||
| Spermicides | |||||||
| Behavioral |
| ||||||
| Experimental | |||||||
Tocolytics/labor repressants (G02CA) | |
|---|---|
| β2 adrenoreceptor agonists | |
| Oxytocin antagonists | |
| NSAIDs | |
| Calcium channel blockers | |
| Myosin inhibitors | |
| Prolactin inhibitors | |
|---|---|
| Anti-inflammatory products for vaginal administration | |
| Androgens (incl. AASTooltip anabolic–androgenic steroid) |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiandrogens |
| ||||||||||||
| |||||||||||||
| Estrogens |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antiestrogens |
| ||||||||
| |||||||||
| Progestogens (and progestins) |
| ||||
|---|---|---|---|---|---|
| Antiprogestogens |
| ||||
| |||||
| GnRH modulators (incl. analogues) |
| ||||
|---|---|---|---|---|---|
| Gonadotropins |
| ||||
| Others (indirect) |
| ||||
| |||||
Urologicals, including antispasmodics (G04B) | |
|---|---|
| Acidifiers | |
| Urinary antispasmodics (primarily antimuscarinics) | |
| Other urologicals | |
| For erectile dysfunction |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| For premature ejaculation |
| ||||||||||||
| |||||||||||||
Drugs used in benign prostatic hyperplasia (G04C) | |
|---|---|
| 5α-Reductase inhibitors | |
| Alpha-1 blockers | |
| Steroidal antiandrogens | |
| Herbal products | |
| Others | |
Hypothalamic-pituitary hormones and analogues (H01) | |||||||
|---|---|---|---|---|---|---|---|
| Hypothalamus |
| ||||||
| Anterior pituitary |
| ||||||
| Posterior pituitary |
| ||||||
| Mineralocorticoids | |
|---|---|
| Antimineralocorticoids | |
| Synthesis modifiers | |
| |
| Thyroid hormones | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antithyroid preparations |
| ||||||||
| |||||||||
| Parathyroid hormone and analogues | |||||||
|---|---|---|---|---|---|---|---|
| Anti-parathyroid hormone agents |
| ||||||
| 30S |
| ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50S |
| ||||||||||||||||||
| EF-G |
| ||||||||||||||||||
| |||||||||||||||||||
| Beta-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases) |
| ||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polypeptides |
| ||||||||||||||||||||||||||||||||||||||||||
| Intracellular |
| ||||||||||||||||||||||||||||||||||||||||||
| Other |
| ||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
| Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis) |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication) |
| ||||||||||||||||
| Anaerobic DNA inhibitors |
| ||||||||||||||||
| RNA synthesis |
| ||||||||||||||||
| |||||||||||||||||
| Other/ungrouped | |
|---|---|
| Wall/ membrane |
| ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular |
| ||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||
| |||||||||||||||||||||||
| Nucleic acid inhibitor |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein synthesis inhibitor |
| ||||||||
| Cell envelope antibiotic |
| ||||||||
| Other/unknown | |||||||||
| Combinations | |||||||||
| |||||||||
| Baltimore I |
| ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepatitis B (VII) | |||||||||||||||||||||
| Multiple/general |
| ||||||||||||||||||||
| |||||||||||||||||||||
| Hepatitis C |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis D | |||||||||
| Picornavirus | |||||||||
| Anti-influenza agents | |||||||||
| Multiple/general |
| ||||||||
| |||||||||
| Capsid inhibitors | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entry/fusion inhibitors (Discovery and development) | |||||||||||||
| Integrase inhibitors (Integrase strand transfer inhibitors (INSTI)) | |||||||||||||
| Maturation inhibitors | |||||||||||||
| Protease Inhibitors (PI) (Discovery and development) |
| ||||||||||||
| Reverse-transcriptase inhibitors (RTIs) |
| ||||||||||||
| Combined formulations |
| ||||||||||||
| Pharmacokinetic boosters | |||||||||||||
| Experimental agents |
| ||||||||||||
| |||||||||||||
Immune sera and immunoglobulins (J06) | |||||
|---|---|---|---|---|---|
| Polyclonal antibodies |
| ||||
| Monoclonal antibodies | |||||
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||